C4 Therapeutics Reports Strong Q4 Results, Extends Cash Runway to 2028, and Advances Lead Clinical Programs
CCCC has more than doubled off its 52-week low of $1.085 on elevated volume (3.9× avg).
Summary
C4 Therapeutics announced strong fourth-quarter and full-year 2025 financial results, significantly extending its cash runway to the end of 2028, and reported key clinical advancements for its lead multiple myeloma program, cemsidomide.
Key Events · Financing and Capital Events · CCCC
-
Extended Cash Runway
Cash, cash equivalents, and marketable securities reached $297.1 million as of December 31, 2025, enabling the company to fund its operating plan to the end of 2028.
-
Lead Program Advancement
The first patient was dosed in the Phase 2 MOMENTUM trial for cemsidomide in multiple myeloma, designed for potential accelerated approval, with enrollment expected to complete in Q1 2027.
-
Strategic Collaboration
C4 Therapeutics entered a clinical trial collaboration with Pfizer for a Phase 1b trial of cemsidomide in combination with elranatamab, expected to initiate in Q2 2026.
-
Partnership Milestone Achieved
The company earned a $2 million milestone payment from Biogen as BIIB145, a C4T-designed BTK degrader, entered clinical development.
Analysis · CCCC · Life Sciences
This 8-K filing, reporting Q4 and full-year 2025 financial results, provides a highly positive update for C4 Therapeutics. The most impactful news is the extension of the company's cash runway to the end of 2028, largely due to a successful October equity offering. This significantly de-risks the company's operations and provides ample time to achieve critical clinical milestones. Furthermore, the initiation of the Phase 2 MOMENTUM trial for cemsidomide, with potential for accelerated approval, and a new clinical collaboration with Pfizer, demonstrate strong progress in its lead multiple myeloma program. The $2 million milestone payment from Biogen also highlights successful partnership execution. These developments collectively strengthen the company's financial stability and clinical pipeline, supporting its long-term strategic roadmap.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCCC was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $268.5M. The 52-week trading range was $1.09 to $3.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.